DeepCure, a Boston, MA-based company developing novel, small molecule therapeutics using an AI drug discovery engine, closed a $40m Series A financing round.
The round was led by Morningside Ventures, with participation from existing investors TLV Partners, Sapir Venture Partners, and Benon Group Ltd.
The company, which has raised a total of $47m in financing since its inception, intends to use the funds to continue to develop its novel small molecule therapeutics pipeline across various disease indications, to build an automated robotic wet lab to complete its vision of end-to-end AI drug discovery, and to double the headcount of its current drug discovery scientists and technologists next year, including a global expansion with the launch of two new sites in Greece and Israel.
Led by Kfir Schreiber, CEO, Joseph Jacobson, Ph.D., Chief Scientific Officer, and Thrasyvoulos Karydis, Chief Technology Officer, DeepCure is developing several novel preclinical candidates across different “undruggable” classes, ranging from polypharmacology programs to protein-protein interactions and previously “impossible” specificity challenges critical in various indications in areas of high unmet medical need.
FinSMEs
09/11/2021